Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve block shots could ease chronic headaches, trial shows

NCT ID NCT07497646

Symptom relief Sponsor: Saglik Bilimleri Universitesi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether repeated injections of a numbing drug (bupivacaine) into the back of the head could help people with chronic migraine or chronic tension-type headache. 290 adults received either the drug or a placebo (salt water) injection over three months. The main goal was to see if the treatment reduced the number of headache days per month.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bupivacaine (a numbing medication)
What this could lead to
If it works, this could offer a non-daily treatment option to reduce headache frequency and pain for people with chronic migraine or tension-type headache.
What could go wrong
This is a completed trial, but results may not apply to everyone. The effect may be modest, and injections carry risks like pain, bleeding, or infection at the site.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

290 people

The number who actually took part.

Started

Jan 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults 18 years or older * Diagnosis of chronic migraine or chronic tension-type headache according to International Classification of Headache Disorders (ICHD-3) criteria * History of headache for at least 3 months prior to enrollment * Ability to provide written informed consent * Willingness to comply with study procedures and follow-up visits Exclusion Criteria: * Secondary headache disorders * Previous greater occipital nerve blockade within the last 3 months * Known allergy or contraindication to bupivacaine * Local infection at the injection site * Coagulation disorders or ongoing anticoagulant therapy that contraindicates injection procedures * Severe uncontrolled systemic disease * Pregnancy or breastfeeding * Participation in another clinical trial within the previous 30 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic migraine headache are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

headache disorder migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic migraine headache Chronic tension-type headache

Contacts and locations

Locations

  • Sultan Abdulhamid Han Research and Training Hospital

    Istanbul, Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.